Loading
Exai Bio's study of small RNAs found in tumours but not normal tissue, read from blood serum to detect lung cancer.
In serum from 1,050 people with non-small cell lung cancer and matched controls, the Orion model achieved an overall sensitivity of 94 per cent (95% CI 87 to 98) at 87 per cent (95% CI 81 to 93) specificity across all stages on held-out validation data.
Tumour-specific small RNAs are readable in serum; the specificity is too low for population screening as reported.
Shares Exai Bio, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Non-small-cell lung cancer.
Shares Exai Bio, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/